<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335378">
  <stage>Registered</stage>
  <submitdate>15/04/2010</submitdate>
  <approvaldate>19/04/2010</approvaldate>
  <actrnumber>ACTRN12610000311055</actrnumber>
  <trial_identification>
    <studytitle>Retinal Artery Study in participants with obstructive sleep apnoea treated with continuous positive airway pressure</studytitle>
    <scientifictitle>A pilot, randomised controlled trial of retinal artery flicker induced vasodilatation to detect change in endothelial function in participants with obstructive sleep apnoea treated with continuous postitive airway pressure for 6 weeks.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endothelial function</healthcondition>
    <healthcondition>Sleep Apnoea</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>6 weeks Continuous Positive Airway Pressure (CPAP) individually titrated and fitted for use during sleep.</interventions>
    <comparator>No CPAP treatment for 6 weeks</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The Dynamic Vessel Analyzer (IMEDOS, Germany) is used to measure retinal vascular endothelial function.  Changes in ocular haemodynamic parameters expressed as the percentage change over baseline values in response to flicker light stimulation.</outcome>
      <timepoint>After 6 weeks of treatment with CPAP or no CPAP</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Moderate to severe Obstructive Sleep Apnoea(OSA) - Apnoea Hypopnoea Index greater than or equal to 30, with associated hypoxaemia  Oxygen saturation(Sa O2) &lt;90% for a minimumm of 6% of total sleep time. 
Actual coronary artery disease or two or more of the following cardiovascular risk factors  hypertension, dyslipidaemia, diabetes, smoking, positive family history.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Commercial driver or patients listed for urgent CPAP implementation.
Glaucoma</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>1. sealed opaque envelopes</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/04/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Austin Health Department of Cardiology and Institute for Breathing and Sleep</primarysponsorname>
    <primarysponsoraddress>Studley Road
Heidelberg VIC 3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Austin Hospital Medical Research Foundation</fundingname>
      <fundingaddress>Studley Road
Heidelberg VIC 3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Evidence has accumulated that changes to the tiny blood vessels at the back of the eye (retinal arteries) are linked to heart disease. It is possible to use a simple eye examination to view these tiny retinal blood vessels and get an idea about their condition. This kind of examination is simple to perform and is not invasive. Because there are similarities to blood vessels throughout the body, an eye examination could be used to provide important information about blood vessel condition in general and whether certain treatments can result in improved blood vessel function.
This study will examine the retinal arteries of a group of patients with Obstructive Sleep Apnoea and risk factors for or actual heart disease. It will also look for evidence that the function of the retinal arteries improves with Continuous Positive Airway Pressure (CPAP) treatment</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress>Studley Road
Heidelberg VIC 3084</ethicaddress>
      <ethicapprovaldate>15/12/2009</ethicapprovaldate>
      <hrec>H2009/03772</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Allison Collins</name>
      <address>Institute for Breathing and Sleep
Bowen Centre
Austin Health
Studley Road Heidelberg VIC 3084</address>
      <phone>+61 3 9496 5756</phone>
      <fax />
      <email>allison.collins@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Allison Collins</name>
      <address>Institute for Breathing and Sleep
Bowen Centre
Austin Health
Studley Road Heidelberg VIC 3084</address>
      <phone>+61 3 9496 5756</phone>
      <fax />
      <email>allison.collins@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>